k PeptiDREAM announces to form a joint venture to develop drugs for COVID19 November 12, 2020, Kawasaki, Japan Japans drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint venture PeptiAID with four companies to development of the new drug for the treatment of COVID19 at the companys headquarters in Kawasaki, suburban Tokyo on Thursday, November 12, 2020. PeptiDream developed PDPS technology to find peptide candidates targeting spike protein of coronavirus to enter human cells. PeptiAID will obtain PeptiDreams COVID19 candidate compounds to enter clinical testing. Photo by Yoshio TsunodaAFLO Editorial Stock Photo - Afloimages
Sign up
Login
All images
PeptiDREAM announces to form a joint venture to develop drugs for COVID 19 November 12, 2020, Kawasaki, Japan   Japan s drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint venture PeptiAID with four companies to development of the new drug for the treatment of COVID 19 at the company s headquarters in Kawasaki, suburban Tokyo on Thursday, November 12, 2020. PeptiDream developed PDPS technology to find peptide candidates targeting spike protein of coronavirus to enter human cells. PeptiAID will obtain PeptiDream s COVID 19 candidate compounds to enter clinical testing.        Photo by Yoshio Tsunoda AFLO
ED

PeptiDREAM announces to form a joint venture to develop drugs for COVID-19

November 12, 2020, Kawasaki, Japan - Japan's drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint venture PeptiAID with four companies to development of the new drug for the treatment of COVID-19 at the company's headquarters in Kawasaki, suburban Tokyo on Thursday, November 12, 2020. PeptiDream developed PDPS technology to find peptide candidates targeting spike protein of coronavirus to enter human cells. PeptiAID will obtain PeptiDream's COVID-19 candidate compounds to enter clinical testing. (Photo by Yoshio Tsunoda/AFLO)

Details

ID
148089344

Collection

License type
Editorial

Creation date
12-11-2020

Contact Aflo for all commercial uses.


Sign in
Member access
Login not found.